Nexalis outlines 2026 plan as IRX shares jump 35% by Adam Sheldon February 17, 2026February 19, 2026 Nexalis Therapeutics Limited – formerly InhaleRx – has used its first investor presentation since formally changing […]
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026February 5, 2026
Elixinol records first underlying operating cash flow positive quarter by Adam Sheldon February 2, 2026February 3, 2026
InhaleRx locks in A$1m cap raise and reveals plans to rebrand by Adam Sheldon December 1, 2025February 21, 2026
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025February 21, 2026
InhaleRx reports half-year loss but advances clinical trial plans by Martin Lane August 26, 2025August 28, 2025
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
